At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 207 enrolled
Drug / intervention
Comparator: rizatriptan benzoate +1 moredrug
Likely dose
Comparator: rizatriptan benzoate 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Clinical Trial to Study the Efficacy and Safety of MK0462 / Rizatriptan 10 mg for the Early Treatment of Acute Migraine
In Brief
A Phase 3 clinical trial evaluating Comparator: rizatriptan benzoate and Comparator: Placebo for Migraine. Completed, enrolled 207 participants.
Detailed Summary
The purpose of this study is to test the effectiveness of rizatriptan benzoate in the early treatment of an acute migraine attack.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartOct 2007
Primary CompletionApr 2008
TodayJul 2026
First PostedAug 15, 2007
Enrollment StartOct 3, 2007
Primary CompletionApr 8, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.9 years ago
Interventions
Comparator: rizatriptan benzoatedrug
Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
Comparator: Placebodrug
Matching placebo; one dose, treatment of a single migraine attack